Metoprolol tartrate is used as a drug for treating high blood pressure which is also known as hypertension. It helps to reduce the high blood pressure to prevent heart strokes, heart attacks, and kidney problems. Metoprolol tartrate is also used for treating chest pain also called angina for improving the survival chances after a heart attack. Metoprolol tartrate belongs to drug class called beta-blocker which works as blocking the action of certain natural chemicals such as epinephrine on heart and blood vessels. This effect lowers the heart rate, blood pressure, and strain on the heart.
The global metoprolol tartrate market is estimated to be valued at US$ 6,101.4 Mn in 2022 and is expected to exhibit a CAGR of 3.3% over the forecast period (2022-2030).
Figure 1: Global Metoprolol Tartrate Market Share (%) Analysis, By Application, 2022
Increasing prevalence of hypertension is expected to drive the global metoprolol tartrate market growth over the forecast period.
Increasing prevalence of hypertension is expected to increase the use of beta blocker medications such as metoprolol tartrate, which is expected to drive the market growth over the forecast period. For instance, on September 27, 2021, according data published by The Centers for Disease Control and Prevention (CDC) stated that in 2019, around half number of adults population in the U.S which is around 116 million were suffering from hypertension which indicated by diastolic blood pressure higher than 80 mmHg, a systolic blood pressure more than 130 mmHg or are taking medication and treatment for hypertension.
Increasing product launch by market players is expected to drive the global metoprolol tartrate market growth over the forecast period.
The increasing product launch by market players is expected to drive the global metoprolol tartrate market growth over the forecast period. For instance, on April 11, 2016, Mylan N.V, a manufacturing company of generic medicines and specialty pharmaceuticals announced the launch of Metoprolol Tartrate Tablets United States Pharmacopeia (USP) which is standard quantity of drug substance or ingredient in form of 37.5 mg tablets and 75 mg tablets, which is the generic version of Lopressor Tablets developed by Novartis. As Metoprolol Tartrate Tablets USP strengths are available in form of 25 mg, 50mg, and 100 mg and these new strengths of 37.5 mg and 75 mg tablets will be a new addition to the metoprolol tartrate market.
|Base Year:||2021||Market Size in 2022:||US$ 6,101.4 Mn|
|Historical Data for:||2017 to 2020||Forecast Period:||2022 to 2030|
|Forecast Period 2022 to 2030 CAGR:||3.3%||2030 Value Projection:||US$ 7,931.7 Mn|
Novartis Pharmaceuticals Canada Inc., AstraZeneca Pharma India Limited, Teva Pharmaceutical Industries Ltd., Mylan N.V., Dr. Reddy’s Laboratories Ltd., Sun Pharmaceutical Industries Inc., CTX Life Sciences Pvt. Ltd., Hikma Pharmaceuticals PLC, Validus Pharmaceuticals LLC, Alembic Pharmaceuticals Limited, Aurobindo Pharma USA, Sandoz Canada Inc., Apotex Inc., Ipca Laboratories Ltd, and Rubicon Research Pvt. Ltd.
|Restraints & Challenges:||
Global Metoprolol Tartrate Market - Impact of the Coronavirus (COVID-19) Pandemic
The COVID-19 pandemic is expected to drive the global metoprolol tartrate market growth, owing to research and development of metoprolol tartrate for treatment of cardio logical complications associated with COVID-19 patients. For instance, on September 7, 2021, an article published in the science direct journal, a database of references and abstracts of life science research stated about the effect of metoprolol on patient of COVID-19 at pilot trial which concluded that intravenous metoprolol administration to patients with COVID-19–associated Acute Respiratory Distress Syndrome (ARDS) was safe and reduced exacerbated lung inflammation, and improved the oxygenation. Repurposing metoprolol for COVID-19–associated ARDS appeared to be a safe and inexpensive strategy that can alleviate the burden of the COVID-19 pandemic.
Global Metoprolol Tartrate Market – Restraints
Product recall for metoprolol tartrates may hamper the global metoprolol tartrate market over the forecast period. For instance, on September 9, 2020, Aurobindo Pharma USA Inc., a manufacturing company of pharmaceutical announced the recall of a single lot of 2820 packaging bottles containing metoprolol tartrate tablets after receiving reports that a metal wire was found in a tablet, Aurobindo Pharma USA voluntarily initiated the recall. The U.S. food and drug administration (FDA) designated the recall Class II on September 20, 2021.
Global Metoprolol Tartrate Market – Regional Analysis
On the basis of region, the global metoprolol tartrate market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.
Among regions, North America is expected to hold a dominant position during the forecast period, owing to the increasing prevalence of cardiovascular diseases. For instance, on March 22, 2021, according to the Division for Heart Disease and Stroke Prevention, a department of the Centers for Disease Control and Prevention published fact sheet for prevalence of hypertension in the U.S., which stated that in the year 2019, approximately 47.3% that is around 116 million of adult population is suffered from hypertension, where around 91.7 million population were treated with medication.
Figure 2: Global Metoprolol Tartrate Market Value (US$ Mn), by Region, 2022
Global Metoprolol Tartrate Market – Competitive Landscape
Major players operating in the global metoprolol tartrate market include Novartis Pharmaceuticals Canada Inc., AstraZeneca Pharma India Limited, Teva Pharmaceutical Industries Ltd., Mylan N.V., Dr. Reddy’s Laboratories Ltd., Sun Pharmaceutical Industries Inc., CTX Life Sciences Pvt. Ltd., Hikma Pharmaceuticals PLC, Validus Pharmaceuticals LLC, Alembic Pharmaceuticals Limited, Aurobindo Pharma USA, Sandoz Canada Inc., Apotex Inc., Ipca Laboratories Ltd, and Rubicon Research Pvt. Ltd.
Metoprolol Tartrate is a selective β1 receptor blocker medication that is designed for the treatment of cardiovascular diseases and hypertension, as it works as slowing down the heart rate and makes the heart more efficient at pumping blood around the body. It is used for treating high blood pressure issues, chest pain due to low blood circulation to the heart, and abnormal heart rate. Metoprolol Tartrate is mostly used in the treatment of Angina pectoris, Cardiac arrhythmias, and thyrotoxicosis. Metoprolol Tartrate is available in two types of formulations including oral and injectable. The generic form of Metoprolol Tartrate is Lopressor. Metoprolol comes in form of immediate-release tablets which are designed to disintegrate and release medicine and extended-release tablets and it is prescribed medicine only.
Increasing prevalence of cardiovascular diseases in various region is expected to drive the global metoprolol tartrate market over the forecast period. For instance, in August 2021, European statistics published data on cardiovascular diseases, stating that in the year 2019, approximately 45,400 bypass surgeries were conducted in Germany. Moreover, in the year 2016, 1.68 million deaths occurred due to cardiovascular diseases in the Europe region. The same data on prevalence of cardiovascular diseases reported that high blood pressure increased in age group from 25 to 34 years and that around 3.4% of the population between this age group in Europe was reported to have hypertensive diseases. Furthermore, more than 54.6% population of hypertension diseases were aged 75 years or older, which is expected to drive demand for metoprolol tartrate in upcoming years.
Key features of the study:
“*” marked represents similar segmentation in other categories in the respective section.